Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Abstract | BACKGROUND: METHODS: A double-blind placebo-controlled randomized trial involving 240 subjects aged 37-87 years with 10-40 actinic keratoses was conducted at eight US academic medical centers. Patients were randomly assigned to receive 200 mg of celecoxib or placebo administered orally twice daily for 9 months. Subjects were evaluated at 3, 6, 9 (ie, completion of treatment), and 11 months after randomization. The primary endpoint was the number of new actinic keratoses at the 9-month visit as a percentage of the number at the time of randomization. In an intent-to-treat analysis, the incidence of actinic keratoses was compared between the two groups using t tests. In exploratory analyses, we evaluated the number of nonmelanoma skin cancers combined and SCCs and BCCs separately per patient at 11 months after randomization using Poisson regression, after adjustment for patient characteristics and time on study. The numbers of adverse events in the two treatment arms were compared using χ(2) or Fisher exact tests. All statistical tests were two-sided. RESULTS: There was no difference in the incidence of actinic keratoses between the two groups at 9 months after randomization. However, at 11 months after randomization, there were fewer nonmelanoma skin cancers in the celecoxib arm than in the placebo arm (mean cumulative tumor number per patient 0.14 vs 0.35; rate ratio [RR] = .43, 95% confidence interval [CI] = 0.24 to 0.75; P = .003). After adjusting for age, sex, Fitzpatrick skin type, history of actinic keratosis at randomization, nonmelanoma skin cancer history, and patient time on study, the number of nonmelanoma skin cancers was lower in the celecoxib arm than in the placebo arm (RR = 0.41, 95% CI = 0.23 to 0.72, P = .002) as were the numbers of BCCs (RR = 0.40, 95% CI = 0.18 to 0.93, P = .032) and SCCs (RR = 0.42, 95% CI = 0.19 to 0.93, P = .032). Serious and cardiovascular adverse events were similar in the two groups. CONCLUSIONS:
Celecoxib may be effective for prevention of SCCs and BCCs in individuals who have extensive actinic damage and are at high risk for development of nonmelanoma skin cancers.
|
Authors | Craig A Elmets, Jaye L Viner, Alice P Pentland, Wendy Cantrell, Hui-Yi Lin, Howard Bailey, Sewon Kang, Kenneth G Linden, Michael Heffernan, Madeleine Duvic, Ellen Richmond, Boni E Elewski, Asad Umar, Walter Bell, Gary B Gordon |
Journal | Journal of the National Cancer Institute
(J Natl Cancer Inst)
Vol. 102
Issue 24
Pg. 1835-44
(Dec 15 2010)
ISSN: 1460-2105 [Electronic] United States |
PMID | 21115882
(Publication Type: Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Anticarcinogenic Agents
- Cyclooxygenase 2 Inhibitors
- Pyrazoles
- Sulfonamides
- Celecoxib
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Anticarcinogenic Agents
(administration & dosage, adverse effects, therapeutic use)
- Carcinoma, Basal Cell
(prevention & control)
- Carcinoma, Squamous Cell
(prevention & control)
- Celecoxib
- Cell Transformation, Neoplastic
- Cyclooxygenase 2 Inhibitors
(therapeutic use)
- Double-Blind Method
- Female
- Humans
- Keratosis, Actinic
(drug therapy, pathology)
- Male
- Middle Aged
- Pyrazoles
(administration & dosage, adverse effects, therapeutic use)
- Skin Neoplasms
(etiology, prevention & control)
- Sulfonamides
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|